MedPlus Health Services Limited has announced its quarterly earnings call to discuss the unaudited financial results for the quarter ended December 31, 2025. The announcement, made on January 22, 2026, follows the company's regulatory obligations under SEBI guidelines for listed entities.

Earnings Call Schedule

The company has scheduled the analyst and institutional investor meet for the Q3FY26 results discussion with specific timing and participation details.

Regulatory Compliance

The earnings call announcement has been made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates listed companies to inform stock exchanges about material events and developments that could impact investor decisions.

Participation Options

MedPlus Health Services has provided comprehensive joining information to facilitate participation from analysts and institutional investors. The company offers two primary participation methods:

Pre-Registration Option

Participants can pre-register through a dedicated online link to join the call without waiting for operator assistance, streamlining the connection process.

Dial-In Access

Traditional dial-in numbers are available for participants who prefer telephone access. The company recommends joining 10 minutes prior to the scheduled time to ensure timely connection.

Information Availability

The earnings call details and joining information will be made available across multiple platforms to ensure broad accessibility. The company has confirmed that all relevant information will be accessible through its official website at www.medplusindia.com , as well as on the official websites of both stock exchanges - BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Limited ( www.nseindia.com ).

The announcement was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, ensuring proper authorization and compliance with corporate governance requirements. This structured approach to earnings communication demonstrates the company's commitment to transparent investor relations and regulatory adherence.

MedPlus Health Services Limited has informed stock exchanges about drug license suspensions affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, its subsidiary, received six suspension orders from drug control authorities in Karnataka and Telangana.

Regulatory Actions and Store Locations

The suspension orders were issued by drug control administration authorities across two states, affecting multiple store locations with varying suspension periods.

Legal Framework and Compliance

The suspension orders were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has disclosed this information in compliance with Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The disclosure follows SEBI circulars SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, which mandate detailed reporting of regulatory actions.

Financial Impact Assessment

The company has quantified the potential revenue loss from these suspensions across all affected stores:

Regulatory Disclosure

MedPlus Health Services has made this disclosure through proper channels to both BSE Limited and National Stock Exchange of India Limited. The information will be available on the company's website at www.medplusindia.com and on the respective stock exchange websites. Company Secretary and Compliance Officer Manoj Kumar Srivastava signed the regulatory filing on January 13, 2026.